Canada markets closed

Resverlogix Corp. (RVX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.05000.0000 (0.00%)
At close: 09:30AM EDT

Resverlogix Corp.

4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Aaron Bradley Cann C.A., CPA, CBVChief Financial Officer211.35kN/AN/A
Dr. Ewelina Kulikowski Ph.D.Chief Scientific Officer250kN/AN/A
Dr. Michael Sweeney M.D.Senior Vice President of Clinical Development530.68kN/A1961
Mr. Donald J. McCaffreyCo-Founder, Chairman, President, CEO & Secretary505.2kN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada.

Corporate Governance

Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.